Company intelligence / Profile preview

Lemonex Inc.

Seoul, Republic of Korealemonexbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Lemonex has completed a Phase 1 clinical trial for LEM-S401 (siRNA therapy) and received approval for a Phase 1 clinical trial of LEM-mR203 (mRNA vaccine for COVID-19) in July 2023. The company is evaluating the safety of the DegradaBALL® mRNA vaccine platform in a Phase I clinical study at Seoul National University Hospital.

Therapeutic areas: GastroenterologyOncologyDermatologyInfectious Diseases
Modalities: mRNA vaccinessiRNA therapeuticsRNA immunotherapy
Industry: Biotech

Drug pipeline

4 assets

LEM-mR203

3 more assets in the full pipeline.

Request access →

Partnerships

CEPI (Coalition for Epidemic Preparedness Innovations)International Vaccine Institute (IVI)

Beyond the preview

Go deeper on Lemonex Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lemonex Inc..

Explore the full profile